key: cord-0856263-m69ceq2t
authors: Dubert, Marie; Visseaux, Benoit; Isernia, Valentina; Bouadma, Lila; Deconinck, Laurène; Patrier, Juliette; Wicky, Paul-Henri; Le Pluart, Diane; Kramer, Laura; Rioux, Christophe; Le Hingrat, Quentin; Houhou-Fidouh, Nadhira; Yazdanpanah, Yazdan; Ghosn, Jade; Lescure, Francois-Xavier
title: Case reports study of the first five patients COVID-19 treated with remdesivir in France
date: 2020-06-30
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.06.093
sha: d86608f2aa0fea87b00d76d7ed9dfaa24fba18de
doc_id: 856263
cord_uid: m69ceq2t

Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as responsible for the COVID-19 outbreak worldwide. Data on treatment are scare and parallels are made between SARS-CoV-2 and other coronavirus. Remdesivir is a broad spectrum antiviral with efficient in vitro activity against SARS-CoV-2 and controversial evidence of clinical improvement in severe COVID-19 patients. We aimed to describe the clinical outcome and virological monitoring of the first five COVID-19 patients admitted in ICU for severe pneumonia related to SARS-CoV-2 and treated with remdesivir in the University hospital of Bichat, Paris, France. SARS-CoV-2 RT-qPCR in blood plasma, lower and upper respiratory tract were monitored. Among the five treated patients, two needed mechanical ventilation and one high flow cannula oxygen. A significant decrease in SARS-CoV-2 viral load from upper respiratory tract was observed in most cases but two died with active SARS-CoV-2 replication in the lower respiratory tract. Plasma samples were positive for SARS-CoV-2 in only one patient. Remdesivir was interrupted for side effects among four patients, including 2 ALT elevations (3 to 5 N) and 2 renal failures requiring renal replacement. This case series of five COVID-19 patients requiring ICU for a respiratory distress and treated with remdesivir, highlights the complexity of remdesivir use in such critically ill patients.

In December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), identified as responsible for the COVID-19 outbreak starting in China (Zhu et al. 2020) .

Betacoronavirus, have been proposed as possible therapeutics for SARS-CoV-2, such as ribavirin and IFNα -2b (Martinez 2020) , lopinavir/ritonavir (Chu et al. 2004; Arabi et al. 2020) , and hydroxychloroquine (Savarino et al. 2006; Chen et al. 2020; Gautret et al. 2020; Wang et al. 2020a) , with controversial results. Remdesivir, a nucleotide analogue prodrug with a broad spectrum antiviral activity (Sheahan et al. 2017; Mulangu et al. 2019) , seems promising for SARS-CoV-2 in-vitro (Wang et al. 2020a) . Two case reports (Holshue et al. 2020 ; Kujawski et al. 2020 ) and a recent clinical study of 54 patients (Grein et al. 2020) showed encouraging results on COVID-19-patients. Conversely, a randomized study did not show significant clinical benefit but probably lacked power (Wang et al. 2020b) . Five patients were treated with compassionate-use remdesivir in our center in Paris, France. Early findings have been previously described for two patients (Lescure et al. 2020 ). Here we describe for the first time the complete follow-up, tolerance and virological monitoring among those five patients.

We enrolled all patients admitted in the University Hospital Bichat-Claude Bernard, Paris, France, between January 24 and March 1, 2020, diagnosed with COVID-19 and treated with remdesivir (Gilead Sciences). Indication criteria for compassionate-use remdesivir were defined with the French national regulatory authorities and French ministry of health: signs of severe illness at diagnosis or subsequent clinical aggravation (respiratory symptoms or general signs). Since March 22, all patients requiring an antiviral treatment are enrolled in the Discovery study (2020-000936-23). The Institutional Review Board of Bichat Hospital approved this report and waived the need for informed consent from individual patients, due to the nature of retrospective chart review and the absence of identifying images or personal/clinical details that compromise anonymity.

All patients received remdesivir via intravenous infusion with a loading dose of 200 mg and a maintenance daily dose of 100 mg for a maximum duration of 14 days. All nasopharyngeal and broncho-alveolar samples were collected on universal transport media (Virocult, Sigma) J o u r n a l P r e -p r o o f and transported in the laboratory within 24h. All RT-qPCR were performed according to the WHO recommended procedure (Corman et al. 2020) after an extraction on MagnaPure (Total NA large volume kit, Roche Diagnostic) from 200 µL of transport media and amplification on an ABI 7500 (Life technologies). Quantification was done using a standardized RNA transcript control obtained from the European Virus Archive Program. Bacterial and mycological investigations were conducted on a separate sample without virological transport media using the usual procedures for bacterial growth. Broncho-alveolar lavages were also tested with a mPCR assay (FilmArray Pneumonia assay, BioFire, BioMérieux) for virus and bacteria detection, and fungal culture with mass spectrometry identification for Aspergillus detection. All samples were processed in a BSL3.

A 31-year Chinese male originating from Wuhan and reporting flu-like symptoms for 6 days was diagnosed with COVID-19 on January 24, 5 days after his arrival in Paris. He was immediately hospitalized with mild lymphopenia (1000 G/L), thrombopenia (146 G/L), and no abnormalities on chest X-ray. The RT-qPCR on nasopharyngeal samples was positive with a SARS-CoV-2 viral load (VL) at 10.5 log10 copies/mL. On illness day 10, he was referred to intensive care unit (ICU) due to oxygen saturation worsening (PO2=58mmHg; flow nasal cannula 4 L/min), and bilateral lung ground glass and alveolar opacities on chest CT-scan with no increase in VL. Remdesivir was started on January 29, 2020 (illness day 11) and was stopped at day 15, because of alamine aminotransferase (ALT) elevation (195UI/L versus 46UI/L before remdesivir administration) and a maculopapular rash. A rapid decline of viral load, from 27.6 Ct to undetectability at day 2 of remdisivir infusion was observed. Skin and liver abnormalities improved within three days after discontinuing treatment. The patient was discharged on February 12.

An 80-year-old tourist originating from Hubei Province, with past medical history of thyroid cancer, presented on January 25 with fever and diarrhea for 4 days. The chest X-ray showed bilateral alveolar opacities but he did not fulfill the COVID-19 case definition at the time.

Airborne and contact precautions were observed and the COVID-19 diagnosis was eventually retained 3 days later. On January 26, an acute respiratory failure with multiple organ failures triggered his admission to ICU. A broad spectrum antibiotherapy was started and adapted for coinfection with a susceptible Acinetobacter baumannii (diagnosed on multiplex PCR and J o u r n a l P r e -p r o o f confirmed by tracheal aspirates culture) and an Aspergillus flavus (tracheal aspirates culture).

Remdesivir was started on January 29 but was discontinued on January 31 as the patient needed renal replacement therapy. The nasopharyngeal viral load decreased from 21.0 Ct before infusion to 28.9 on day 2 of infusion. CT-scan on January 31 showed bilateral alveolar condensations, ground glass and pulmonary cysts. On February 5, because of the disease severity and the persistence of viral detection, remdesivir was re-initiated. Multiple organ failures persisted without any other coinfection identified. He died on February 14.

A 39-year old male airport worker, obese (BMI=33kg/m 2 ) and with obstructive sleep apnea syndrome was diagnosed with severe COVID-19 and admitted to ICU on February 26. He had cough and fever since February 21. He presented an acute respiratory failure (PaO2=74mmHg; high debit nasal cannula 40 L/min, 40%) and basal interstitial syndrome on chest X-ray. Remdesivir was started on February 27. Virus RNA levels slightly increased, from 32.5 to 28.8 Ct, during the first 4 days of infusion and started to decline at day 5 later until undetectability On March 1, he was referred to Infectious Diseases ward and was weaned off oxygen on illness day 13. VL was reduced below the RT-qPCR detection limit on day 14. Remdesivir was discontinued after 8 administrations, because of ALT elevation (116 UI/L versus 43UI/L before remdesivir administration) and a maculopapular rash. These symptoms resolved five days after remdesivir discontinuation and the patient was discharged on illness day 20.

A 76-year French male, known for chronic kidney injury (creatinine=115µmol/L, normal range=50-70µmol/L), was admitted on February 22 for cough and fever for 24 hours and transferred in our center on February 26 after diagnosis of COVID-19. He presented a SpO2=92% on air and pulmonary posterior ground glass on chest CT scan. On illness day 11, he was transferred in ICU due to oxygen saturation worsening (PO2=69mmHg; flow low nasal cannula=3 L/min). The nasopharyngeal viral load was already very low at 38.5 Ct but remdesivir was initiated on March 3 and discontinued on March 12, without any side effect, as SARS-CoV-2 VL was constantly negative. He was weaned off oxygen on illness day 19 and discharged on illness day 23. 

This case series of five COVID-19 patients requiring ICU for a respiratory distress treated with remdesivir, three (#1, #3, #4) had a favorable outcome despite the initial respiratory severity. They were weaned off oxygen between illness day 14 to 19 and discharged between illness day 20 and 26. Patients #2 and #5 died in ICU on illness day 25 and 31 with multiorgan failure. Remdesivir initiation yielded a decrease in nasopharyngeal VL in all but patient #2, for whom the treatment was re-introduced after an early interruption without additional decrease neither in upper nor lower respiratory tract. For patient #5, a viral replication was still ongoing in the lower respiratory tract despite a concomitant undetectable VL in the nasopharyngeal area, thus highlighting the discrepancies between viral replication in upper and lower respiratory tract among the most severe patients. Plasma samples were only positive for SARS-CoV-2 for patient #2.

As described in previous case reports (Grein et al. 2020; Kujawski et al. 2020) , four out of five patients experienced major side effect under remdesivir (two acute renal injuries and two maculo-papular rash with a cytolytic hepatitis). Both kidney failure events could be either related to remdesivir or SARS-CoV-2 infection. None of our patients received immunomodulatory drugs. Grein et al. (Grein et al. 2020 ) described 53 COVID-19-patients

Ethics approval and consent to participate

The present report has been approved by the French Ethics Committee (NCT04262921).

Consent for publication: The Institutional Review Board of Bichat Hospital approved this report and waived the need for informed consent from individual patients, due to the nature of retrospective chart review and the absence of identifying images or personal/clinical details that compromise anonimity.

Availability of data and materials : The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request For each patient, type of hospital ward is indicated by the color rectangles, supplemental O2 requirement by the dashed blue line and remdesivir infusion by the red line. Viral load is given with black diamonds and black line for nasopharyngeal swabs, with green squares for lower respiratory tract samples when available and red circles for plasma samples. The viral load is estimated by the Ct (cycle threshold) values. The lower the Ct value, the higher is the viral load. A sample is negative above 40 Ct. 

Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Diagnostic detection of 2019-nCoV by realtime RT-PCR -protocol and preliminary evaluation as of

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Novel Coronavirus in the United States

First 12 patients with coronavirus disease 2019 (COVID-19) in the United States. medRxiv

Clinical and virological data of the first cases of COVID-19 in Europe: a case series

Compounds with therapeutic potential against novel respiratory 2019 coronavirus

Controlled Trial of Ebola Virus Disease Therapeutics

New insights into the antiviral effects of chloroquine

Broadspectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet

A Novel Coronavirus from Patients with Pneumonia in China

J o u r n a l P r e -p r o o f